Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 127Carcinoma, Non-Small-Cell Lung 57Squamous Cell Carcinoma of Head and Neck 46Neoplasms 41Head and Neck Neoplasms 38Neoplasm Metastasis 31Pancreatic Neoplasms 15Colonic Neoplasms 14Lung Neoplasms 13Carcinoma, Squamous Cell 13Breast Neoplasms 13Rectal Neoplasms 12Recurrence 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Ovarian Neoplasms 8Melanoma 7Stomach Neoplasms 6Carcinoma, Renal Cell 6Carcinoma 6Solid Tumors 5Gastrointestinal Neoplasms 5Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Sarcoma 4Neoplasms, Squamous Cell 4Laryngeal Diseases 4Advanced Solid Tumor 4Hereditary Sensory and Autonomic Neuropathies 3Carcinoma, Pancreatic Ductal 3Uterine Cervical Neoplasms 2

Interventions

sapanisertib 2MLN 8237 2tovorafenib 1serabelisib 1pevonedistat 1TAK 733 1Paclitaxel 1Irinotecan 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Nonhematologic Malignancies × Cetuximab × Clear all
NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Takeda

Phase 1 Completed
81 enrolled 33 charts

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡